Journal of Leukemia
Open Access

Department of Lymphoid Malignancies, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA

Publications

• Mini Review   
  Highly Specific JAK3 Inhibitors and the Future of T Cell Lymphoma Treatment
  Author(s): Wei Chen*
  
  Janus kinse-3 (JAK3) exclusively associates with common gamma chain (γc) receptor of γc-cytokines. When γc cytokines, such as IL-2, IL-15, IL-21, IL-4, IL-7 and IL-9, bind their receptors, JAK3, in combination with JAK1 and downstream signal transducers and activators of transcription, STATs, initiate critical signaling cascades. These pathways underlie the hematopoiesis, proliferation and differentiation of normal hematopoietic cells. Conversely, the aberrant, constitutive activation of the JAK-STAT signaling pathways, including JAK3’s, is associated with immune related disorders and cancers. Thus, inhibition of JAK-STAT signaling and their downstream tyrosine kinases have provided a therapeutic approach for treatment of several hemopoietic malignancies, especially T cell lymphomas. These cells typically harbor activating JAK mutations that lead to increased J.. View More»
  DOI: 10.35248/2329-6917.22.10.311

  Abstract HTML PDF